Application No:

[For internal WMA use only]



WMA Therapeutic Use Exemption (TUE)

Standard international application form

This form is used to apply for approval to use a substance or method that is on the WADA prohibited (banned) list for therapeutic (medical) purpose.

Please complete all sections

[PRINT information legibly using BLOCK capitals]

Section 1 - Your information

First Name:	Last Name:
Female Male (tick appropriate box)	Event:
Address:	
City: Country:	
Post Code	e-mail:
Tel. Home: Mobile:	
Date of birth (d/m/y):	
National Federation:	

City:			•	
Address: City: Country				
Post Codee-mail: Tel. Work:				
Post Codee-mail: Tel. Work:	ddress:			
Tel. Work:	City:		Country	
Diagnosis (see Note 2 – you must attach evidence and clinical details) Section 4 - Medication details Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin 1. Route of Administration: Administration: Administration:	ost Code e-ma	il:		
Diagnosis (see Note 2 – you must attach evidence and clinical details) Section 4 - Medication details Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Dose of Administration: Administration: Administration:	el. Work:			
Section 4 - Medication details Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: A	lobile:	Fax:		
Diagnosis (see Note 2 – you must attach evidence and clinical details) Section 4 - Medication details Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin 1. Route of Administration: Administration: Administration:				
Diagnosis (see Note 2 – you must attach evidence and clinical details) Section 4 - Medication details Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin 1. Route of Administration: Administration: Administration:	action 2 Madical information			
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: A	ection 5 - Medical Information	1		
Prohibited medication Dose of Route of Frequency of (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1.	Diagnosis (see Note 2 – you mus	st attach evidence and	clinical details)	
Prohibited medication Dose of Route of Frequency of (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1.				
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: A				
Prohibited medication Dose of Route of Administration: Commercial name/Generic name e.g: Humuline@/Insulin Commercial name/Generic name e.g: Humuline@/Insulin				
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: A				
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin Dose of Administration: Administration: Administration: Administration:	I and the second			
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin Dose of Administration: Administration: Administration: Administration:		•••••		
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: Administration: Administration:				
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: Administration: Administration:				
Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline@/Insulin 1. Route of Administration: Administration: Administration:				
(see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin Administration: Administration: Administration:				
(see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin Administration: Administration: Administration:	ection 4 - Medication details			
Commercial name/Generic name e.g: Humuline©/Insulin 1.				
name e.g: Humuline©/Insulin 1.	Prohibited medication		Route of	
	Prohibited medication (see Notes 3 and 4):		Route of	
2.	Prohibited medication (see Notes 3 and 4): Commercial name/Generic		Route of	
	Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin		Route of	
3.	Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin 1.		Route of	
J	Prohibited medication (see Notes 3 and 4): Commercial name/Generic name e.g: Humuline©/Insulin 1.		Route of	

Section 5 - Additional information		
D ' WIT (()		1
Previous TUE request(s)	yes	no (tick appropriate box)
If yes: Date:		
Organisation (to whom TUE	lication oplicable)	as sent) Result
(attach previous TUE(s) where		

Section 6 - Medical Practitioner's Declaration

Signature of Medical Practitioner:	Date:
Specify reasons:	
condition (see Note 5).	
Internal Control of the Control of t	
WADA Prohibited List would be unsatisfactory for the treatr	ment of the abovenamed medical
named medical condition. I further certify that the use of a	alternative medications not on the
above-named athlete has been/are to be administered as th	e correct treatment for the above-
I,	ntioned medication(s) for the

Section 7 - Athlete's declaration

I, certify that the information in section 1 above is accurate
and that I am requesting for approval to use a prohibited substance or prohibited method in
the WADA Prohibited List. I authorize the release of my personal medical information to the
members of the WMA Therapeutic Use Exemption Sub-Commission (WMA TUESC), as well
as to any other relevant persons (including, where applicable, WADA or IAAF staff and/or
members of the WADA or IAAF Therapeutic Use Exemption Committees) who may be
involved in the management, review or administration of my application in accordance with
the IAAF Procedural Guidelines. I understand that, if I ever wish to revoke the right of the
WMA TUESC to obtain any health information on my behalf, I must notify my medical
practitioner in writing of the fact. As a consequence of such a decision, I understand that I will
not receive approval for a TUE (or renewal of an existing TUE).
I further authorise for the decision of the WMA TUESC to be notified to other relevant organisations in accordance with IAAF Rule 34.5.
Athlete's signature: Date:

Send to:

Carole Filer
71 Hunter House Road
Sheffield. S11 8TU
Gt Britain

Mob: **0044 (0) 754 882 6151** e.mail: <u>wmatuesec@gmail.com</u>

Note 1	Name, qualifications and medical specialty
	For example: Dr AB Cook, MD FRACP, Gastro-enterologist.
	Dr JA Gonzalez, MBBS, FACSM, Sports Physician

Note 2	<u>Diagnosis</u>
	Evidence confirming the diagnosis must be attached and forwarded with this application. The medical evidence should include clinical history, examination, investigations or specialist medical reports. Copies of original reports or letters should be included when possible. Evidence should be as objective as possible in the clinical circumstances and, in the case of nondemonstrable conditions, independent supporting medical opinion will assist this application.
Note 3	Medication details
	Please provide details concerning all medications or treatments that have been tried. Provide both the commercial and generic name (INN) of the medication and specify the medication dose, the route of administration and the frequency of administration.
Note 4	<u>Change of Prescription</u> Note that a new TUE application is required for any change in prescription
Note 5	If a permitted medication can be used in the treatment of the athlete's medical condition, please provide clinical justification for the requested use of the prohibited medication.

<u>WARNING</u>: Incomplete Applications will be returned and will need to be re-submitted.

Please submit the completed form to the WMA TUE Coordinator (contact details below) and keep a copy of the form for your records:

Carole Filer
71 Hunter House Road
Sheffield. S11 8TU
Gt Britain

Mob: **0044 (0) 754 882 6151** e.mail: <u>wmatuesec@gmail.com</u>

If there are further questions arising from this Form or regarding the relevant procedures for standard applications for TUEs on an international level, please contact Carole Filer at wmatuesec@gmail.com_(e-mail).